XML 24 R73.htm IDEA: XBRL DOCUMENT v2.4.0.8
Acquisitions - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified
12 Months Ended 0 Months Ended 12 Months Ended 12 Months Ended 0 Months Ended 12 Months Ended 0 Months Ended 12 Months Ended 12 Months Ended 0 Months Ended 12 Months Ended 12 Months Ended
Sep. 30, 2014
Sep. 30, 2014
Medical [Member]
Sep. 30, 2014
Biosciences [Member]
Sep. 30, 2014
Diagnostics [Member]
Mar. 11, 2013
Cato [Member]
Sep. 30, 2014
Cato [Member]
Mar. 11, 2013
Cato [Member]
Sep. 30, 2014
Cato [Member]
Medical [Member]
Dec. 24, 2012
Safety Syringes [Member]
Sep. 30, 2014
Safety Syringes [Member]
Dec. 24, 2012
Safety Syringes [Member]
Sep. 30, 2014
Safety Syringes [Member]
Medical [Member]
Aug. 24, 2012
Sirigen Group Limited [Member]
Sep. 30, 2014
Sirigen Group Limited [Member]
Aug. 24, 2012
Sirigen Group Limited [Member]
Sep. 30, 2014
Sirigen Group Limited [Member]
Minimum [Member]
Sep. 30, 2014
Sirigen Group Limited [Member]
Maximum [Member]
Sep. 30, 2014
Sirigen Group Limited [Member]
Patent [Member]
Sep. 30, 2014
Sirigen Group Limited [Member]
Developed technology [Member]
Sep. 30, 2014
Sirigen Group Limited [Member]
Biosciences [Member]
Feb. 09, 2012
KIESTRA Lab Automation BV [Member]
Sep. 30, 2014
KIESTRA Lab Automation BV [Member]
Feb. 09, 2012
KIESTRA Lab Automation BV [Member]
Sep. 30, 2014
KIESTRA Lab Automation BV [Member]
Core and Developed Technology [Member]
Sep. 30, 2014
KIESTRA Lab Automation BV [Member]
Diagnostics [Member]
Business Acquisition [Line Items]                                                  
Percentage of outstanding shares acquired             100.00%       100.00%       100.00%               100.00%    
Acquisition-date fair value of consideration transferred net of in cash acquired         $ 23 $ 23     $ 124 $ 124     $ 64 $ 64             $ 58 $ 58      
Fair value of consideration transferred in cash         14       124       53               49        
Fair value of contingent consideration             9               12               9    
Developed technology           9       69       19               13      
Risk-adjusted discount rate           14.50%       16.00%               20.00% 22.00%     14.50%      
Amortization of technology, expected useful life           15 years       15 years               14 years 16 years     10 years      
Goodwill 13       13   11   11   34   34   34           34   35     35
Portion of goodwill currently expected to be deductible for tax purposes           0       34       0               0      
Acquisition-related costs in the current period   4 1     1       2       1               2      
Cash acquired in acquisition                     1       1               5    
Fair value of consideration transferred for effective settlement of an intangible asset                     0.4                            
Gain/loss recognized on settlement                 0                                
Patent                           11                      
Acquired in-process research and development                           12               7      
Technological and commercial risk                           80.00%               100.00%      
Risk-adjusted discount rate used to determine fair value of in-process research and development assets acquired                               24.00% 26.00%         15.50%      
Purchase price adjustment recorded in fiscal year 2013                                           $ 2      
Amortization of finite lived intangible assets, expected useful life                                               10 years